Lactobacillus reuteri DSM 17938 is effective in the treatment of functional abdominal pain in children: Results of the double-blind randomized study.
Abdominal pain
Children
Functional gastrointestinal disorders
L. reuteri DSM 17938
Probiotics
Journal
Clinical nutrition (Edinburgh, Scotland)
ISSN: 1532-1983
Titre abrégé: Clin Nutr
Pays: England
ID NLM: 8309603
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
received:
23
01
2020
revised:
05
04
2020
accepted:
08
04
2020
pubmed:
5
5
2020
medline:
20
8
2021
entrez:
5
5
2020
Statut:
ppublish
Résumé
Possible therapeutic effect of Lactobacillus (L.) reuteri DSM 17938 has been reported in children with functional abdominal pain (FAP) but data are inconclusive. This is a randomized double-blinded controlled trial (RCT) which assessed effect of L. reuteri DSM 17938 (dose 10 This RCT included 46 children (median age 10.1 vs 10.6 years; 11 vs 13 girls). Abdominal pain was less severe in intervention group during the 4th month of the study and there was significant increase in the number of days without pain. Pooled data from both parts of the study included 101 children. Number of days without pain was significantly higher in the L. reuteri group (mean difference 26.42 days, 95% CI 22.47-30.17). Significant difference in the pain intensity was found after 2nd, 3rd and 4th month of the intervention. There was no difference between groups in the number of children in whom symptoms completely ceased (Risk Ratio 1.09, 95% CI 0.75-1.58). Administration of L. reuteri DSM 17938 was associated with the reduction in the intensity of pain and with significantly increase in pain-free days in children with FAP.
Sections du résumé
BACKGROUND & AIMS
Possible therapeutic effect of Lactobacillus (L.) reuteri DSM 17938 has been reported in children with functional abdominal pain (FAP) but data are inconclusive.
METHODS
This is a randomized double-blinded controlled trial (RCT) which assessed effect of L. reuteri DSM 17938 (dose 10
RESULTS
This RCT included 46 children (median age 10.1 vs 10.6 years; 11 vs 13 girls). Abdominal pain was less severe in intervention group during the 4th month of the study and there was significant increase in the number of days without pain. Pooled data from both parts of the study included 101 children. Number of days without pain was significantly higher in the L. reuteri group (mean difference 26.42 days, 95% CI 22.47-30.17). Significant difference in the pain intensity was found after 2nd, 3rd and 4th month of the intervention. There was no difference between groups in the number of children in whom symptoms completely ceased (Risk Ratio 1.09, 95% CI 0.75-1.58).
CONCLUSION
Administration of L. reuteri DSM 17938 was associated with the reduction in the intensity of pain and with significantly increase in pain-free days in children with FAP.
Identifiants
pubmed: 32362486
pii: S0261-5614(20)30190-4
doi: 10.1016/j.clnu.2020.04.019
pii:
doi:
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3645-3651Informations de copyright
Copyright © 2020 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.
Déclaration de conflit d'intérêts
Conflict of interest Iva Hojsak received payment/honorarium for lectures or consultation from BioGaia, Nutricia, Nestle, Chr Hansen, Biocodex, Oktal Pharma; Sanja Kolaček received fees for lectures from Abbott, AbbVie, Fresenius, Mead and Johnson, Nestle, Nutricia, Oktal Pharma, Shire; Zrinjka Mišak travel grants and lecture fees from Abbvie, Wurth, GlaxoSmithKline, PharmaS; Oleg Jadrešin, Sara Sila, and Ivana Trivić declare no conflict of interest.